Skip to main content

Table 4 Disease modifying anti-rheumatic drugs: biologics

From: Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data

Agent FDA pregnancy category Adverse effects in human pregnancy Summary risk assessment
Etanercept B No documented increased risk for structural defects Based on minimal data in human pregnancy, teratogenic risk is undetermined
Infliximab B   
Adalimumab B   
Rituximab C No documented increased risk for structural defects based on case report Based on lack of data in human pregnancy, teratogenic risk is undetermined
Anakinra B No available human data Based on lack of data in human pregnancy, teratogenic risk is undetermined